Log in

BJDX Bluejay Diagnostics, Inc. NASDAQ · United States

Bluejay Diagnostics (BJDX) news BJDX reverse split and offering news

Latest Bluejay Diagnostics news

  1. Company Updates

    Bluejay reports SYMON-II baseline patient characteristics

    The preliminary analysis covers 777 evaluable patients with an overall 28-day mortality rate of approximately 18%. The company says the baseline data do not yet establish the test's performance.

  2. Company Updates

    Bluejay signs federal distribution partnership with Lovell Government Services

    Lovell will be Bluejay's exclusive distributor for federal procurement opportunities that favor veteran-owned small businesses, once its products receive FDA clearance or other required authorization.

  3. Financings

    Bluejay reports Q2 2026 results and $9.6 million in cash

    The company says its June 2026 private placement brought in about $7.6 million in net proceeds and that its cash should fund operations through the second quarter of 2027.

  4. Company Updates

    Bluejay completes SYMON-II enrollment of 750 patients ahead of plan

    Preliminary observations show an approximately 17% 28-day mortality rate in the enrolled population. The company expects to complete data cleaning, statistical analysis and clinical reporting over the coming months.

  5. Listings

    Bluejay stockholders approve reverse split authority

    Stockholders approved a reverse split at a fixed ratio between 1-for-2 and 1-for-20, but the board has no present intention to carry it out in the next 12 months.

  6. Company Updates

    Bluejay announces U.S. manufacturing partnership with Argonaut

    The strategic partnership with Argonaut Manufacturing Services aims to build U.S.-based manufacturing for the Symphony platform and reduce reliance on overseas sourcing.

  7. Company Updates

    Bluejay gives first quarter 2026 corporate update

    About 680 patients were enrolled in SYMON-II as of May 5, 2026, toward a target of 750, and the company reported a first-quarter net loss of approximately $1.9 million.

Bluejay Diagnostics annual financials

LineFY2025FY2024
Research and development$3.0 million$3.5 million
Net income (loss)-$6.8 million-$7.7 million
Cash from operations-$6.1 million-$7.8 million
Cash and equivalents$5.2 million$4.3 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.6 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Bluejay Diagnostics

Did Bluejay Diagnostics do a reverse stock split?

Our latest story on this, dated Jun 9, 2026: "Bluejay stockholders approve reverse split authority". The story links the filing or release it is based on. Read the story.

Has Bluejay Diagnostics raised money recently?

Our latest story on this, dated Aug 13, 2026: "Bluejay reports Q2 2026 results and $9.6 million in cash". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Bluejay Diagnostics?

Bluejay Diagnostics, Inc. trades under the ticker BJDX on NASDAQ.

Where is Bluejay Diagnostics listed?

Bluejay Diagnostics, Inc. is listed on NASDAQ.

Which country or territory is Bluejay Diagnostics listed under?

Our directory records Bluejay Diagnostics, Inc. under United States.

Does aibio.space cover Bluejay Diagnostics?

aibio.space lists Bluejay Diagnostics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Bluejay Diagnostics profitable?

Bluejay Diagnostics, Inc. reported a net loss of $6.8 million for the fiscal year ended Dec 31, 2025, and used $6.1 million of cash in operations, per its annual report to the SEC.

How much does Bluejay Diagnostics spend on research and development?

$3.0 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Bluejay Diagnostics have?

$9.6 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Bluejay Diagnostics (BJDX) stock news?

Our latest story on Bluejay Diagnostics, dated Oct 13, 2026: "Bluejay completes Toray manufacturing site ahead of deadline". Bluejay Diagnostics said it finished establishing a Symphony cartridge manufacturing site under its amended Toray license, ahead of an October 23, 2026 deadline. Source.

How long will Bluejay Diagnostics's cash last?

From our story of Aug 13, 2026: The company says its June 2026 private placement brought in about $7.6 million in net proceeds and that its cash should fund operations through the second quarter of 2027. Source.

How can I follow Bluejay Diagnostics (BJDX) news?

Press Follow on this page to add Bluejay Diagnostics to your Following list, or subscribe to the aibio.space newsletter. We have published 8 stories naming Bluejay Diagnostics so far, in Company Updates, Financings, Listings.

Investor discussion: Bluejay Diagnostics

Members talk about Bluejay Diagnostics (BJDX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Bluejay Diagnostics, newest first. Each line links the filing it comes from.

  1. Financings

    Reported a financing. SEC Form 8-K (Items 7.01,9.01). Source

  2. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source

  3. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source

  4. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:BJDX on TradingView.

Listing details

Bluejay Diagnostics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BJDX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Bluejay Diagnostics, Inc.
Ticker
BJDX
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.